The intestinal tract is a site of intense immune cell activity that is poised to mount an effective response against a pathogen and yet maintain tolerance toward commensal bacteria and innocuous dietary antigens. The role of cell death in gut pathologies is particularly important as the intestinal epithelium undergoes self-renewal every 4-7 days through a continuous process of cell death and cell division. Cell death is also required for removal of infected, damaged, and cancerous cells. Certain forms of cell death trigger inflammation through release of damage-associated molecular patterns.
| INTESTINAL TRACT-AN IMMUNOLOGICAL TIGHT ROPE
The intestinal tract presents an environment that experiences multitude of antigenic stimuli from microbial, dietary, and environmental products. A single-layered intestinal epithelium separates the underlying immune system from these potent triggers to maintain an equanimous environment. The immune system must apprehend and respond to pathogenic stimuli while maintaining tolerance against non-pathogenic antigens. This equilibrium between inflammatory and tolerogenic immune response needs to be perfectly calibrated, and unregulated tipping of this balance can lead to deleterious consequences, like inflammation and cancer. The host employs several mechanisms to restrain unwarranted immune activation and yet mount an appropriate immune response when required. First, a sparsely colonized 50-to 100-μm mucus layer termed as the "demilitarized zone" physically separates microbiota and the epithelium.
Second, the immune system that resides within the intestinal tract has through multiple mechanisms acquired a tolerogenic phenotype toward non-pathogenic stimuli. Third, the host is armed with several anti-microbial mechanisms ranging from secretory antibodies (IgA) to anti-microbial peptides (AMPs) and phagocytosis to neutralize a pathogen.
Many lines of evidence suggest a causal relation between inflammation and colorectal cancer (CRC). First, patients with inflammatory bowel disease (IBD) are at a significantly higher risk for development of CRC.
1,2 Second, multiple anti-inflammatory drugs such as anti-TNF antibodies and non-steroidal anti-inflammatory drugs (NSAIDs)
reduce the incidence of CRC in human patients. promote DNA damage, aberrant cellular proliferation, angiogenesis, and metastasis ( Figure 1 ). 5 Coordinated processes of cellular proliferation, migration, and angiogenesis are also involved in wound healing and injury repair, and tumors are, therefore, considered as "wounds that do not heal." 6 The innate immune system forms a critical line of defense that needs to respond to a diverse range of stimuli, mount a rapid and dynamic response to combat an insult, and promote tissue repair ins such as IL-1α and HMGB1. 7 The inflammasome activation, therefore, leads to removal of infected and/or damaged cells and production of inflammatory mediators that together combat the infectious or sterile insult.
| CELL DEATH PATHWAYS
Cell death has been observed as a pathological feature within inflamed tissue and was largely considered to be a consequence of inflammation. Recent studies have, however, identified cell death as an instigator and modulator of inflammation. Not surprisingly, cell death is a complex, well-regulated process with huge implications under both homeostatic and pathophysiological conditions. While earlier literature considered apoptosis as an "immunologically silent"
and coordinated event, necrosis was considered as incidental cell death with no defined molecular mechanisms. Recent studies have, however, clarified this long-held misconception and multiple forms of regulated necrotic cell death pathways such as necroptosis, ferroptosis, and NETosis have been defined. 8 Necroptosis and pyroptosis involve the formation of pores in the cell membrane 9 that leads to loss of osmotic potential, cytoplasmic swelling, and the release of intracellular contents. The accompanying release of DAMPs provides a pro-inflammatory characteristic to these forms of cell death ( Figure 2 ).
| Apoptosis
Apoptosis is considered an immunologically silent form of programmed cell death that can be triggered by cell-intrinsic factors, such as DNA or mitochondrial damage, and extrinsic factors, such as engagement of death receptors. Intrinsic apoptosis utilizes caspase-9 as the initiator caspase, while the extrinsic pathway uses caspase-8. Apoptosis ultimately involves activation of executioner caspases, caspase-3, and caspase-7 that cleave the cellular contents and neutralize their inflammatory potential until scavenging cells can phagocytose the dying cell.
F I G U R E 1 Pro-tumorigenic functions of inflammation: While controlled inflammation is required to both clear pathogenic insults and repair tissue damage, uncontrolled inflammation can lead to tumorigenesis through multiple mechanisms. Production of growth factors, anti-apoptotic, and pro-survival factors signal to promote survival and proliferation of neoplastic cells. Inflammation also causes DNA damage through production of reactive oxygen species (ROS) and iNOS. Production of matrix metalloproteases (MMPs) and other proteases degrades extracellular matrix to promote migration and invasion of cancer cells. Furthermore, angiogenic factors promote the formation of blood vessels that provide oxygen and nutrients to the rapidly dividing cancerous cells
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Unsurprisingly, aberrations in the apoptotic pathways can lead to increased inflammation due to the breakdown of the epithelial barrier or cancer due to non-removal of neoplastic cells (reviewed in 10,11).
Apoptosis is also involved in the killing of cancer cells by chemotherapeutic drugs and radiotherapy (reviewed in 12).
| Pyroptosis
Pyroptosis is induced in response to caspase-1 activation within the inflammasome complex and caspase-11 (caspase-4/5 in humans) activation following intracellular LPS recognition. Caspase-1 and caspase-4/5/11 induce pyroptosis through cleavage and oligomerization of GSDMD. [13] [14] [15] [16] Caspase-1/4/5/11 can, therefore, be considered as initiator caspases, while GSDMD acts as the executioner molecule.
GSDMD has a caspase cleavage site that releases its active N-terminus subunit, allowing it to undergo oligomerization, insert into the cellular membrane, and form pores (10-14 nM in size). [13] [14] [15] [16] The formation of pores leads to loss of osmotic potential, cytoplasmic swelling, and release of intracellular contents. Pyroptotic cell death can be inhibited by glycine that restricts loss of osmotic potential and consequent death. 9, 17 Expression of N-terminus domain of GSDMD is sufficient to induce pyroptosis in mammalian cells [13] [14] [15] [16] and death in bacterial cells. 15, 16 GSDMD-induced pyroptosis further allows release of active forms of cytokines, IL-1β and IL-18, and alarmins such as IL-1α. 13, 14 GSDMD belongs to a family of proteins that share 45% sequence homology, and the active N-terminus domain is conserved among most of its members. The human genome encodes for GSDMA, GSDMB, GSDMC, GSDMD, GSDME (DFNA5) and DFNB59, and all but DFNB59 have the N-terminus domain that can potentially induce cell death in mammalian cells. 13, 15 The expression of the GSDM family members is specifically localized to the epithelium of skin and gastrointestinal (GI) tract. 18 Further, GSDMD and GSDMC are differentially expressed along the proximal-distal axis within the GI tract with highest expression observed in the duodenum. 18 Within esophageal and gastric cancer cells, the expression pattern suggests that GSDMA, GSDMC, and GSDMD could be potential tumor suppressors while GSDMB, which was overexpressed, could be an oncogene. 19 Through a similar strategy of expression and promoter (methylation pattern)
analysis in CRC cell lines, GSDME was identified as a tumor suppressor and molecular marker for colon cancer. 20, 21 The exact consequence of the expression pattern or the role of these homologs in cell death and GI pathologies has not been defined yet. Any deductions regarding the role of pyroptosis in gut pathologies are extrapolated from the role of inflammasome components. Pyroptosis is required for inflammasomemediated cell death and release of IL-1β and IL-18 in vitro, 13, 14 and it remains to be seen whether similar dependence on pyroptosis or GSDMD (or another GSDM molecule) exists in vivo during intestinal pathologies. Further, whether inflammasome-mediated cell death and cytokine release have distinct immunological consequences remains unknown. Identification of the pyroptosis executioner during in vivo pathologies will allow the investigators to delineate the effects of cell death vs cytokine release following inflammasome activation.
A recent study demonstrated that GSDME-expressing cells undergo pyroptosis in response to chemotherapy through caspase-3 mediated activation of GSDME. 22 This switch from apoptotic to pyroptotic cell death has inflammatory implications as Gsdme −/− mice were protected from chemotherapy (cisplatin)-induced tissue damage and weight loss. 22 This suggests that the GSDM molecules may be downregulated by cancer cells to evade cell death and that promoting their expression could overcome resistance to chemotherapeutic drugs.
| Necroptosis
Receptor interacting protein kinase 1 (RIPK1) acts as a molecular switch between apoptosis and necroptosis forms of cell death. This process has been well described with respect to tumor necrosis factor receptor 1 (TNFR1)-mediated signaling. 23, 24 In response to trim- 
| INFLAMMASOMES IN INTESTINAL PATHOLOGIES: IMPLICATIONS FOR PYROPTOSIS
The family of cytosolic receptors that engage in inflammasome platforms includes NLRs, ALRs, and Pyrin. The NLR family is characterized by N-terminus pyrin domain (PYD) or caspase activation and recruitment domain (CARD) and C-terminus leucine repeat rich (LRR) motif.
This family includes extensively characterized inflammasomes such as NLRP3, NLRC4, and NLRP1 and other putative inflammasomeforming proteins such as NLRP6, NLRP12, and NLRP9b. 39 Other molecules such as NLRP6 40 and NLRP12 41, 42 also have signaling functions independent of the inflammasome assembly. The ALR family is named after its conventional member, absent in melanoma 2 (AIM2)
Necroptosis pathway of cell death. Necroptosis can be triggered by multiple stimuli, including TNF, LPS (through TRIF), and dsRNA, and is mediated by the executioner molecule, mixed lineage kinase-like (MLKL). During necroptosis, receptor interacting protein kinase 1 (RIPK1) interacts with another kinase, receptor interacting protein kinase 3 (RIPK3) through RIP homotypic interaction motif (RHIM) mediated interaction, leading to activation and autophosphorylation of RIPK3. RIPK3 binds to and phosphorylates MLKL, p-MLKL undergoes oligomerization and membrane translocation to induce membrane depolarization and cell death. RIPK1 also induces a pro-survival signal through NFκB activation that is positively regulated by cellular inhibitor of apoptotic protein (cIAP). Deubiquitination by A20, and cylindromatosis (CYLD) switches the prosurvival signal to apoptotic cell death through Fas-associated protein with death domain (FADD)-Caspase-8 complex. Caspase-8 activity is inhibited by its enzymatically inactive homolog, cellular FLICE-like inhibitory protein (cFLIP). However, if RIPK1 pro-survival signal and caspase-8 activity are both compromised, RIPK1 activates RIPK3 to induce necroptosis T A B L E 1 (Continued)
| NLRP3
Triggers for activation of NLRP3 inflammasome include a wide array of microbial products such as microbial cell wall components-lipopolysaccharide (LPS) and muramyl dipeptide (MDP), nucleic acids, poreforming toxins, and damage-associated molecular patterns (DAMPs), such as ATP and uric acid crystals. 63, [69] [70] [71] As the NLRP3 inflammasome assembles in response to a vast range of DAMPs, it is likely that it senses a common cellular distress signal induced by these molecules, activation is also protective in colitis induced by another hapten, oxazolone, in a manner dependent on the production of both IL-1β and IL-18 production. 79 In contrast to these studies, other studies have reported protection from DSS or TNBS-induced colitis or AOM-DSS-induced CAC in mice deficient in the NLRP3 inflammasome components or IL-18
signaling. [80] [81] [82] [83] [84] The discrepancies in the phenotypes observed by different groups could be due to differences in microbial composition in different animal facilities, precise genetic backgrounds of the knockout mice, and experimental protocols. However, despite having a normalized microbiota profile when cohoused with WT mice, caspase-11 deficient mice are still more susceptible to DSS-induced colitis. 106 Therefore, further studies are needed to clarify the mechanisms by which caspase-11 protects from DSS-induced colitis.
| NAIP-NLRC4
NLRC4 inflammasome is activated through sensing of flagellin and T3SS by NAIPs (NLR family apoptosis inhibitory protein). [48] [49] [50] [51] [52] [53] The role of NLRC4 in CRC is controversial with independent studies demonstrating no role 3 or a protective role 107 in colorectal tumorigenesis. Loss of NAIPs1-6, specifically in epithelial cells, leads to increased tumor burden that is associated with lower anti-apoptotic and higher proliferative response following AOM exposure. 108 While no difference in inflammasome response is detected in the absence of NAIPs, tumor tissue isolated from NAIP1-6-deficient mice exhibits increased expression of pro-inflammatory cytokines, MMPs, and genes associated with tumor growth and invasion. 108 In contrast to increased tumorigenesis, mice deficient in NAIP1-6 are protected from acute DSS-induced colitis. F I G U R E 4 NLRP3 inflammasome activation. NLRP3 activation is a two-step process, involving priming and inflammasome assembly. The priming of NLRP3 inflammasome involves transcriptional upregulation of NLRP3 and its posttranslational modifications. In response to cognate stimuli, primed NLRP3 interacts with the adapter, ASC, which recruits caspase-1 to assemble a multimeric complex known as the NLRP3 inflammasome. Caspase-1 undergoes autocatalytic cleavage within the complex to yield its active subunit. Active caspase-1 cleaves pro-IL-1β and pro-IL-18 into their bioactive forms. The executioner molecule, Gasdermin-D (GSDMD), mediates pyroptosis. GSDMD is cleaved by caspase-1 to yield its active N-terminus domain that oligomerizes and inserts into the cell membrane. Cell death is caused by loss of osmotic potential which leads to cell rupture and release of intracellular contents. This makes pyroptosis a potent pro-inflammatory mechanism of cell death resistance to bacterial colonization is independent of IL-1 and IL-18 cytokines, implicating cell death as the mechanism that controls bacterial invasion. 111 Another study, however, demonstrated that increased mortality in Nlrc4 −/− can be phenocopied by Il1r −/− mice, with IL-1R signaling being protective in orogastric Salmonella infection through neutrophil recruitment. 112 Systemic recognition of Salmonella or flagellin also induces hypothermia and diarrhea through eicosanoid production in response to NLRC4 activation. 110, 113 Cytosolic delivery of flagellin (FlaTox) similarly triggers NLRC4 inflammasome activation and associated pathology. 113 The pathology is associated with expulsion of epithelial cells through NLRC4 and redundant on caspase-1 and caspase-8 activation. 110 Importantly, loss of Casp-1-GSDMD (in epithelial cells) axis prevents lytic death but not intestinal cell expulsion or intestinal pathology. 110 Genetic loss of NLCR4 or ASC/Casp1/Casp11 protects against cell expulsion and inflammatory consequences. 110 Therefore, while NLRC4 activation is required to restrict bacterial invasion, it also causes pathology through inflammatory cell death. NLRC4 also synergizes with NLRP3
to restrict bacterial burden and associated pathology during C. rodentium infection despite not being involved in inflammasome activation in macrophages. 100 NLRC4 is required within the non-hematopoietic cells to restrict early colonization and innate response to Citrobacter infection. 114 Mutations in NLRC4 are associated with enterocolitis and autoinflammation in humans, [115] [116] [117] and incidence of severe neonatal enterocolitis was associated with a de novo mutation in the NLRC4 gene. 115 This mutation results in spontaneous ASC oligomerization, caspase-1 processing, cell death and release of inflammatory cytokines, IL-1β, and IL-18. 115 Regulation of NLRC4 activation is, therefore, critical during enteric infections and autoinflammatory disorders.
| AIM2
AIM2 was identified as an IFNγ-inducible protein in a tumor suppressor screen and only later redefined as an inflammasome-forming ALR, specifically in response to dsDNA. 44 The authors also link lower inflammasome activation and IL-18 production in Aim2 −/− mice to increased IL-22BP and decreased AMP production, predisposing Aim2 −/− mice to microbial dysbiosis and increased susceptibility to colitis. 120, 121 Contrary to previous studies, 118,119 the authors did not observe any differences in epithelial cell death in the absence of AIM2. 120 While AIM2 is protective in CAC, its precise role in colitis varies depending on the genetic background and/ or husbandry conditions. However, even under co-housed conditions (normalized microbiota), Aim2 −/− mice have increased tumor burden compared with the WT controls. 119 Therefore, the synergy between microbiota and AIM2 mediated cell-proliferative signaling controls colitis and colon tumorigenesis.
| NLRP1
The murine genome encodes for three paralogs (Nlrp1a-c) of the human NLRP1 gene, of which NLRP1b forms an inflammasome platform in response to B. anthracis lethal toxin 55 and Toxoplasma gondii. However, certain inflammatory mediators also execute a reparative process by promoting pathogen expulsion, epithelial cell proliferation, anti-microbial peptide (AMP), and mucus production that help restore the integrity of the epithelial barrier. The activation of these inflammatory cell death pathways, therefore, needs to be tightly regulated to promote anti-pathogenic responses without causing excessive damage to the barrier recombinant IL-18 and IL-1β ameliorates the histological damage. 123 Increased cell death and impaired epithelial barrier function were observed in Nlrp1b −/− mice following DSS-induced damage. 123 NLRP1b also functions primarily within the non-hematopoietic compartment to restrict colon tumorigenesis. 123 Genetic association studies have identified NLRP1 mutations linked to Crohn's disease that affect its auto-proteolytic cleavage and activity. 124 Further studies into structural modifications and proteolytic activity of NLRP1 mutants would help delineate the molecular mechanisms involved in its activation and its functions in gut physiology.
| NLRP6
NLRP6 is highly expressed in both small and large intestine of mice 125, 126 and in the small intestine of humans. 85 Another study demonstrated that NLRP6 is expressed by the myofibroblasts within stem cell niches and is critically required for epithelial stem cell proliferation and migration, events necessary for reparative processes following mucosal damage induced by DSS. 125 This function contributes to the susceptibility of Nlrp6 −/− mice to colorectal tumorigenesis. 125 Another mechanism proposed for the antitumorigenic role for NLRP6 is restriction of CC-motif chemokine ligand-5 (CCL5) IL-6 axis that promotes epithelial signal transducer and activator of transcription-3 (STAT-3) activation and proliferation. 130 NLRP6 also functions in the inflammatory monocytes to protect from DSS-induced colitis by promoting IL-18 production. 131 Therefore, NLRP6 can function through multiple mechanisms to restrict colitis and CAC.
NLRP6 is also expressed in the goblet cells and is required for effective autophagy and associated mucus exocytosis. 126 Consequently, Nlrp6 −/− , Asc −/− , and Caspase1/11 −/− mice exhibit altered goblet cell function and lack a thick, continuous mucus layer. 126 Abrogated mucus secretion into the lumen decreases the capacity of Nlrp6 −/− mice to clear enteric infections and resolve inflammation. 126 This role of NLRP6 in the promotion of mucus barrier was confirmed in another study that demonstrated that NLRP6 activation in a specialized "sentinel goblet cell" is required to induce secretion of the mucin muc2, a major component of intestinal mucus layer. 132 NLRP6 activation in this instance was triggered upon endocytosis of TLR ligands such as LPS and flagellin and mediated by ROS production. 132 The authors, however, noted that NLRP6 and inflammasome-deficient mice did not exhibit discontinuous inner mucus layer, 132 unlike previously noted. 126 In addition to microbial ligands, microbial metabolites have also been shown to modulate NLRP6 activation within the colonic microenvironment. Microbe-derived metabolite taurine was shown to positively engage NLRP6 activation, while histidine and spermine inhibit NLRP6 activation. 133 Decreased IL-18 production due to abrogated NLRP6 activation leads to an altered AMP landscape that further promotes microbial dysbiosis and colitogenic response. 133 Another study suggests that NLRP6 restricts abundance of mucin-degrading microbe, Akkermansia muciniphila through IL-18 production and thereby reduces spontaneous colitis in Il10 −/− mice. 134 Surprisingly, the authors demonstrate that co-housing does not equilibrate Akkermansia colonization and colitis susceptibility. This study identified level of Akkermansia colonization as the critical determinant of colitis susceptibility in Il10 −/− mice and shows that the abundance of Akkermansia is actively regulated by NLRP6-IL-18 axis. 134 Contrary to the above-mentioned observation, a recent study did not find a role for NLRP6 in regulating the gut microbial landscape (in two geographically distinct facilities) or susceptibility to DSSinduced colitis. 135 The authors found no differences in the fecal microbial landscape, or DSS-induced colitis in F2 Nlrp6 −/− and Nlrp6
littermates even after the gut microbiota of these mice had the opportunity to evolve in the preweaning phase, and then for 1 year in separately housed setting. 135 The observed changes in the microbial landscape were instead driven by cage and maternal covariants. 135 These studies underline the use of littermates as a prelude to studying the effect of a gene on microbial alterations and enteric immunity. The precise role and function of NLRP6, therefore, requires careful consideration.
| NLRP12
NLRP12 was identified as a factor capable of modulating NFκB activation and ASC speck formation. 136 Although certain studies have suggested an inflammasome function for NLRP12, 137 ,138 most studies have described an inhibitory role for NLRP12 in MAPK and non-canonical NFκB activation. 41, 42 The increased susceptibility to colitis and CAC in the absence of NLRP12 is linked to enhanced MAPK and NF-κB signaling. 41, 139 Expression of NLRP12 in both hematopoietic and non-hematopoietic cells is required to restrict inflammation, while it functions predominantly within the nonhematopoietic compartment to inhibit tumorigenesis. 139 NLRP12
was shown also to interact with TRAF3 and NIK to restrain noncanonical NFκB signaling. 139 NLRP12 expression itself is downregulated during DSS-induced inflammation through the TLR4-Blimp1 axis, perhaps to promote inflammatory response during colitis. 140 A subsequent study showed that Nlrp12 −/− mice exhibit low level of inflammation and decreased microbial diversity under homeostatic conditions, which predisposes them to DSS-induced colitis.
141
NLRP12 functioned primarily in the hematopoietic compartment to restrain colitis and microbial dysbiosis. 141 WT and Nlrp12 −/− mice raised under germ-free conditions have similar susceptibility to DSS-induced colitis, suggesting that the primary function of NLRP12 is to maintain a symbiotic gut microbial community. 141 Antibodies against pro-inflammatory cytokines (IL-6 and TNF) and reconstitution with commensal Lachnospiraceae isolates could both correct colitis and microbial dysbiosis, highlighting the synergy between the immune system and the microbiota in determining susceptibility to colitis. 141 Contrary to its protective role in colitis and CAC, NLRP12
suppresses host immunity to enteric infections. 42 The absence of NLRP12 leads to increased inflammatory signaling and antimicrobial activity in response to Salmonella infection, which promotes effective clearance. 42 Therefore, NLRP12-mediated inhibition of inflammatory signaling can have both protective and pathogenic functions in enteric responses based on the inflammatory trigger.
| NLRC3
Like NLRP12, NLR family CARD-containing 3 (NLRC3) has also been described as a non-inflammasome-forming NLR that negatively regulates inflammatory and cell-proliferative signaling. cell proliferation during AOM-DSS challenge. 145 In vitro studies suggest that NLRC3 reduces the activation of the PI3K p85 subunit by disrupting its association with the p110α subunit. 144 Further, reduced apoptotic cell death is observed in colons of Nlrc3 −/− mice and could contribute to increased tumorigenesis. 145 The implications of this negative regulation of the PI3K-mTOR pathway by NLRC3 in other intestinal or extra-intestinal disorders will be an interesting area of research.
| NLRP9b
NLRP9b is a newly identified putative inflammasome sensor that mediates host defense against enteric rotavirus infection. 39 Like NLRP6, NLRP9b is highly expressed in the epithelial cells of the small intestine and in a mechanism analogous to DHX15 and 
| CASPASE-8: BEYOND APOPTOSIS
| NECROPTOSIS IN THE GUT
A significant overlap exists between signaling nodes that modulate inflammation, cell survival, and cell death. This suggests that an interplay between these biological processes functions to maintain homeostasis and prevent deleterious consequences. NFκB signaling and receptor interacting protein kinase 1 (RIPK1) are examples of such signaling modules that regulate inflammatory signaling and fate of the cell.
The NF-κB pathway controls transcription of multiple genes involved in inflammation and cell survival. 159 Under resting conditions, NF-κB dimers are held in an inactive state in the cytoplasm. NF-κB activation follows two pathways with distinct regulators and biological outputs. Microbial or viral stimuli activate IKKα/β complex that phosphorylates IκB, leading to its ubiquitination and proteasomal degradation. The liberated NF-κB dimers translocate to the nucleus to initiate the transcription programming. The IKK complex in addition to the catalytic subunits, IKKα, and IKKβ also contains a regulatory subunit IKKγ (NEMO) that is required for NF-κB activation. 160 NF-κB activation induces genes involved in immunity, blocking apoptosis, and inducing proliferation, making it a critical node in promoting inflammation and cell survival. [167] [168] [169] Consistent with this innate cell-intrinsic role of RIPK3, RHIM-domain-mediated cytokine production within the dendritic cell compartment (CD11c) and not the kinase activity (necroptosis) is required for protection against DSS-induced damage. 170 TNF-induced toxicity is, however, mediated by epithelial RIPK3, as RIPK3 IEC-KO mice are resistant to systemic effects of TNF. 171 Therefore, RIPK3 controls cell death and production of inflammatory mediators (pro-repair or pro-damage) to regulate epithelial cell immunity ( Figure 5 ).
Another example of the critical intersection of NFκB signaling and cell death in gut physiology is observed in IEC-specific A20 knockout mice challenged with DSS. 172 A20 is a ubiquitin editing enzyme that enacts a negative feedback control on NF-κB signaling, including its activation downstream of RIPK1. Loss of A20 sensitizes the epithelial cells to TNF-induced apoptosis and leads to loss of barrier integrity and inflammatory response to commensal bacteria following DSS administration. 172 Further, transgenic expression of A20 in IECs is protective against DSS-induced colitis, through restrained inflammation 175 Consistent with the pro-tumorigenic role of unrestrained NF-κB activation highlighted in this study (albeit in a spontaneous genetic model), 175 enterocyte and myeloid cell-specific deletion of IKKβ decreases tumor burden in the AOM-DSS model of CRC. 176 Loss of IKKβ in enterocytes increases apoptosis of carcinogenexposed cells, while myeloid-specific IKKβ loss reduces the production of pro-tumorigenic and inflammatory mediators. 176 CYLD deficiency similarly leads to increased NF-κB activation, pro-inflammatory gene induction, and increased susceptibility to colitis and CAC. 177 Molecules of the necroptosis and NF-κB pathway are, therefore, elegantly poised to control inflammation, cell survival, and cell death and thereby affect multiple physiological processes in the gut.
| CONCLUSION
Over the decades, much progress has been made in our understanding of the mechanisms and consequences of various forms of cell death.
The fact that many immortalized cell lines lack molecules involved in cell death pathways suggests that subverting these programs is an important step toward immortalization. The interplay between cell death, inflammation, and damage can be harnessed to (a) trigger cell death in cancers recalcitrant to existing chemotherapeutics, (b) switch the form of cell death between "silent" and "inflammatory" to promote immune surveillance, and (c) temper cell death in a way that it provides the benefit of an immune response to a pathogen, but does not cause excessive damage to the host tissue. Nowhere are these processes of continuous self-renewal and cell death more relevant in the mammalian system than in the intestinal tract. Furthermore, some of these implications can be extended beyond the intestinal pathologies to liver, skin, and blood disorders.
One confounding factor when studying intestinal disorders in animal models is the impact of gut microbiota. The gut microbiota can influence all aspects of gut physiology and disorders, and variations in the resident microflora in different mouse facilities lead to discrepancies in experimental outcomes. Use of appropriate controls such as littermates and rigorous strategies to delineate the "genetic" effect from "stochastic variations in microbiota" is essential to understand the true function of a molecule in shaping the gut microbial landscape and intestinal disorders. While we discussed aspects of synergy between gut microbiota and immune system in the context of gut pathologies, multiple studies have also uncovered a role for this synergy in regulating immunity and physiology at extra-intestinal sites. Finally, we recognize that the transition from mouse models to human patients would have to also consider the heterogeneity in genetic makeup, microbiome, dietary preferences, and medical history within the affected population. The intersection of cell death and the immune response is nonetheless an area of research that is exciting both from the standpoint of basic biology and therapeutic interventions.
